CRISPR and the high conservation of the spliceosome components facilitate the mimicking of human pathological mutations in splicing factors of model organisms. The degenerative retinal disease Retinitis Pigmentosa (RP) is caused by mutations in distinct types of genes, including missense mutations in splicing factors that provoke RP in an autosomal dominant form (s-adRP). Using CRISPR in C. elegans, we generated mutant strains to mimic RP mutations reported in PRPF8 and SNRNP200. Whereas these inherited mutations are present in heterozygosis in patients, C. elegans allows the maintenance of these mutations in homozygosis, which is advantageous for genetic and drug screens. We found that snrp-200(cer23[V676L]) and prp-8(cer14 [H2302del] ) display pleiotropic phenotypes, including a reduced fertility.
INTRODUCTION
Retinitis Pigmentosa (RP) is a rare disease with a prevalence of approximately 1 in 4000 individuals. Thus, this disease is causing progressive loss of vision to more than 1 million people worldwide. RP causes defects in photoreceptors (rods and cones) leading to apoptosis of these cells and degeneration of the retina (1) . Although sporadic RP may occur, most of the RP patients present inherited mutations through diverse modes of genetic transmission. For all these RP familial cases, autosomal dominant is the most common form of genetic inheritance. To date, mutations in 26 genes have been linked with autosomal dominant Retinitis Pigmentosa (adRP) (2, 3), and 7 of these genes encode splicing factors.
The spliceosome is probably the most complex cellular machine. More than 200 proteins are part of this highly dynamic macromolecular complex that removes introns from eukaryotic pre-mRNAs (4) . The spliceosome consists of small nuclear ribonucleoproteins (complexes of snRNAs (U1, U2, U4, U5 and U6) and proteins) that form the core of the spliceosome and have multiple associated proteins. Interestingly, the seven splicing-related genes linked with adRP, encode proteins present in the U4/U6•U5 tri-snRNP complex, which is involved in the assembly of the catalytic spliceosome (5) . These seven proteins are PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, SNRNP200 and RP9. All genes, but RP9, encode proteins highly conserved from C. elegans to humans.
RP patients carrying mutations in these splicing factors do not show any other pathologies or phenotypes associated producing a paradox that is not completely solved yet: mutations in genes expressed ubiquitously present a disease in a specific tissue, the retina (6) . No reliable treatment or therapy is available to treat RP patients.
Thus, a better understanding of the molecular and cellular consequences of s-adRP mutations would help to address this problem, in s-adRP patients at least. However, there are two main handicaps in the study of these mutations, (i) the time-scale in which the disease progresses, and (ii) the essential nature of splicing factors that often hampers genetic and cellular studies. In this study, we propose the use of CRISPR in C. elegans to investigate s-adRP mutations and to explore therapies for RP. Importantly, we have found that these mutations are viable in homozygosis, facilitating functional studies and large-scale screens.
RP patients within the same family, and therefore carrying the same mutations, often present the onset of the disease at different age and the disease progresses differently among the family members. Such variability can be explained by the existence of modifiers, which are mutations or polymorphisms in other genes that influence onset and progression of the disease (7) . As an example, family members harboring the same mutation in PRPF31, present the ages of onset of the disease between 21 and 63 (8) .
Our study proposes the use of C. elegans as model to (i) identify potential modifiers of the splicing-related RP, which could contribute to a better prognosis of patients, and (ii) to identify drugs that could alleviate or accelerate the disease.
RESULTS

Splicing-related RP missense mutations engineered in C. elegans
PRPF8 and SNRNP200 are two of the seven genes associated to autosomal dominant Retinitis Pigmentosa (adRP) (9) . Several mutations in these two genes have been identified in distinct families at different countries (10) (11) (12) (13) (14) (15) (16) . Whereas PRPF8 mutations are in the C-terminal end of the protein, SNRNP200 mutations are present in central helicase domains (Figure 1A) .
We first produced the C. elegans missense mutation corresponding to PRPF8[R2310G], which is a mutation that has been identified in South African and Spanish families (17, 18) (Figure S1A) . As a result of this attempt, we isolated the C. elegans prp-8(cer22[R2303G]) allele that resemble the PRPF8[R2310G] mutation ( Figure 1B) .
Unintentionally, we also identified the prp-8(cer14[H2309del]) allele, which consist of a 4nt deletion/1nt insertion (or small indel) that remove the Histidine 2309 (2302 in C. elegans), an amino acid that is important to maintain the interactions of PRPF8 with other proteins, and it is also mutated in s-adRP patients (17, 19) (Figure 1B) ( Figure   S1 ).
The C-terminal end of PRPF8, in which adRP mutations are located, is the region that interacts with SNRNP200 (10) . We decided to reproduce adRP mutations in the SNRNP200 C. elegans ortholog snrp-200 reasoning that their molecular effect could be similar to PRPF8 mutations. Thus, we produced the snrp-200 alleles cer23[V676L] and cer24[S1080L], corresponding to patient's mutations SNRPN200[V683L] and SNRPN200[S1087L] respectively ( Figure 1B) (Figure S1B ).
Phenotypes of adRP mutations in C. elegans
The four mutant strains mentioned above can be maintained in homozygosis.
However, we observed that these strains seemed to grow slower. We formally tested this observation at distinct temperatures, and we found that the four strains presented a slight postembryonic developmental delay, more prominent at 25 • C and in animals carrying the prp-8(cer14) and snrp-200(cer23) alleles (Figure 2A , S2) ( Table 1) . These two alleles, cer14 and cer23 also displayed a variety of developmental defects at low penetrance, including larval arrest, larval morphological defects and dumpy animals ( Figure S3 ). We also scored the fertility of the s-adRP mutants at 25 • C since mutations in splicing factors commonly display stronger penetrance at that temperature (20, 21) .
We observed that prp-8(cer14) and snrp-200(cer23) animals presented a reduction of the progeny size (Figure 3A, 3B) ( Table 1) . Then we studied the fertility of prp- 8(cer14) at permissive (15 • C) and restrictive (25 • C) temperatures and concluded that cer14 is a temperature-sensitive allele that cause sterility at 25 • C and a reduced brood size at 15 • C ( Figure 3B) . We investigated the cause of the sterility of prp-8(cer14) mutants and found that these animals do not develop the germline properly, presenting shortened germline that does not even made the U-turn ( Figure 3C) .
As a summary of the phenotypic characterization, we described two types of mutations, being prp-8(cer22) and snrp-200(cer24) weak alleles, and prp-8(cer14) and snrp-200(cer23) strong temperature-sensitive alleles. Weak alleles are useful to screen for synthetic interactions as means of identification of modifiers of the disease whereas the strong alleles are convenient in the search of drugs that can alleviate the mutant phenotype.
RNAi screen for modifiers of s-adRP mutations
Since s-adRP mutations affect core proteins of the spliceosome, we reasoned that reduced or altered functions of other spliceosome components might increase the harmful effect of s-adRP mutations. Consequently, partial loss-of-function mutations or polymorphisms in other splicing factors could act as modifiers of the disease. Thus, we made a library of RNAi clones targeting 98 splicing factors that were assayed in wild-type, and in prp-8(cer22) and snrp-200(cer24) animals, which are the two mutant strains harboring weak alleles. All the RNAi clones were tested in duplicate on solid media, in 24-well plates, in wild-type and mutant backgrounds. In this first screen, we identified three genetic interactions with the prp-8(cer22) mutants ( Figure 4A) . No interactions were observed with the snrp-200(cer24) allele.
We validated and quantified these genetic interactions in bigger plates and in duplicates. We confirmed that prp-8(cer22) animals were smaller (developmental arrest) than wild type when exposed to isy-1(RNAi) (Figure 4B, 4D) . Moreover, we determined that prp-8(cer22) mutants presented a reduced fertility in cyn- 15(RNAi) and mog-2(RNAi) when compared with control animals (Figure 4C, 4D) .
In summary, we identified genetic interactions that were specific for a mutant strain and found that these interactions affect different aspects of worm development since one produce growth delay, and the other two reduced fertility.
Next, we wondered if common polymorphisms of ISY1 (isy-1 human ortholog) and PPWD1 (cyn-15 human ortholog) could functionally interact with the prp-8(cer22[R2303G]) mutation (22) . We selected residues with polymorphisms from the top 20 most prevalent polymorphisms in healthy humans using in silico tools that predict the effect of amino acid changes on proteins (23, 24) . By CRISPR, we introduced the single amino acid changes isy-1(cer114[G170S]) and cyn- 15(cer119[D74Q] ) and these mutations were combined with prp-8(cer22) to produce double mutant strains ( Figure S4 ). We did not observe any synthetic interaction, but our experiment illustrates the possibility of easily testing the effect of human polymorphisms, which may potentially modify the onset or the progression of the disease.
Drugs screen
RP patients present a progressive loss of visual field through their life and we reasoned that a drug with an even slight positive effect on our C. elegans mutants would cause delay in the progression of the disease, resulting in a better quality of life for patients.
We used a library with 929 drugs, 91.8% approved by the FDA, and therefore hits that would be validated in other pre-clinical models would easily be transferred to the clinic. Synchronized L1 animals were exposed to 10 µM of each drug and grown on dead bacteria at 25 • C in liquid medium. The effect of the drug in wild-type and prp-8(cer14) mutant animals was scored at adult stages ( Figure 4A) . To better characterize the efficacy of our collection of drugs, after three days of exposure we quantified the locomotor activity of the worms for 15 minutes using the wmicrotracker device (25) .
We observed that drugs causing an obvious phenotype also affected the locomotor activity of the animals and, consequently, drug effect could also be detected by an automated detection of locomotion ( Figure S5) .
The aim of our screen was to find any molecule capable of rescuing the sterile phenotype of prp-8(cer14). We observed a phenotype in wild-type animals for 146 of the 929 drugs tested (about 16%), validating the functional activity of the library, but we did not observe any clear rescue of the prp-8(cer14) sterility.
Instead, we observed that four molecules (Doxycycline hydrochloride, Flutamide, Dequalinium Chloride and Dronedarone hydrochloride) caused a stronger effect on mutants than in the wild-type animals. Such finding is also of clinical interest since the use of these drugs in humans is approved and RP patients could use a drug that may accelerate the progression of their disease. We further tested these four drugs on solid media with all s-adRP strains and only one of these drugs, Dequalinium Chloride (DQ), which is commonly used as antiseptic, was consistently harmful to s-adRP mutants.
After validations, the adverse effect of DQ was consistently reproduced in the two snrp-200 mutants only, and at specific concentrations of the drug (Figure 5B, 5C, S6 ).
DISCUSSION
There are six splicing factors mutated in RP that are highly conserved in C. elegans. We chose PRPF8 and SNRNP200 because these two proteins physically interact through the C-terminal region of PRPF8, where the s-adRP mutations are located (10) . Moreover, RNAi of their orthologs in C. elegans, along with PRPF6, showed the most penetrant phenotypes (26) . These three genes encode proteins of the U5 complex and, based on our previous RNAi experiments, would be more prone to harbor missense mutations with a strong phenotype than the other three splicing factors (PRP3, PRPF31 and PRPF4), which are part of the U4 complex. In fact, PRPF31 is the only s-adRP gene that admits a deletion of the gene causing RP by haploinsufficiency (27) .
In humans, s-adRP mutations cause defects that provoke degeneration of photoreceptors in the retina through a very slow process (28) . Such slowness is a handicap in the modeling of the disease and hampers the understanding of the molecular mechanisms of the pathology.
As drawback to our animal model, C. elegans lacks photoreceptor-like cells.
Photoreceptors are non-dividing cells that are constantly renewing components of the outer segment membrane disc, which implies an intense transcriptional activity and metabolic rate (29) . Similarly, cells in C. elegans also present increased metabolic rate (30) and high transcriptional levels during larval development (31) . Importantly, since C. elegans s-adRP mutations can be maintained as homozygous, it is possible to perform experiments with hundreds or thousands of mutant animals allowing the screening for genetic modifiers or drugs that could either alleviate or exacerbate the phenotype.
Our C. elegans models for s-adRP mutations rely on a single change on amino acids that are conserved from nematodes to human. Such extraordinary conservation would imply maintenance of the function and therefore the missense mutations could have similar consequences at the molecular level in humans and in nematodes. C. elegans has already been exploited as model for s-adRP (26) and would be further exploited in the future if functional replacement of C. elegans s-adRP genes at its endogenous locus can be achieved with their human counterparts. The challenge here would be to express a functional human splicing factor at endogenous levels without causing any phenotype in the nematode. Alternatively, if the functional replacement cannot be complete, a fraction of the protein could be replaced. Thus, we recently humanized the pladienolide binding domain of sftb-1/SF3B1 to make C. elegans sensitive to this drug without causing any other effect in the animal (32) .
The existence of modifiers of s-adRP would explain the distinct penetrance of the disease. A potential modifier has been identified for s-adRP patients with mutations in PRPF31 (33) . Asymptomatic patients with PRPF31 mutations correlate with lower levels of CNOT3, which is a transcriptional regulator of PRPF31. In this case, CNOT3 is a modifier in trans-that would modify the effect of any mutation in the gene PRPF31, but not mutations in other s-adRP genes.
Invertebrate animal models as C. elegans and Drosophila melanogaster are powerful genetic systems to study genetic modifiers. In the case of RP, Drosophila has already been used to identify candidate genetic modifiers of a missense mutation in the fly ortholog of human rhodopsin (34) .
Our RNAi screen identified genetic interactions with prp-8(cer22) but we did not obtain any hit in the snrp-200(cer24) background. This result reinforces the idea that genetic modifiers of the s-adRP disease could be gene specific, or even mutationspecific since diverse PRPF8 s-adRP mutations have distinct effect in PRPF8 stability and location (35) . Still, the existence of universal modifiers of s-adRP is possible but they have not been found yet. Therefore, the lack of a list for global modifiers of the disease complicates the prognosis of RP patients.
RNAi inactivation, which mimic a partial loss-of-function effect, uncovered a synthetic interaction between isy-1, cyn-15 and mog-2 and the prp-8(cer22) allele but did not show any synthetic effect in snrp-200(cer24) mutant animals. Interestingly, the genetic interaction of prp-8(cer22) with isy-1/ISY1 gave a different phenotype (growth defects) than the interactions with mog-2/SNRPA1 and cyn-15 /PPWD1 (reduced fertility). Since PRPF8 is the biggest protein of the spliceosome, and it is present in most of the splicing steps (36), the activity of the candidate genetic modifiers may not be restricted to a single splicing mechanism. ISY1 is part of the NTC complex that participates in precatalytic and catalytic spliceosome. SNRPA1 is at the U2 complex, whose main role is the recognition of the 3' splice site, but it is also present in the catalytic spliceosome (C complex). PPWD1 is one of the Peptydil Prolyl isomerases of the spliceosome and it is also present in the catalytic spliceosome (37, 38) .
We mimicked in C. elegans two human polymorphisms that may affect the structure of ISY1 and PPWD1, but we did not detect any interaction with prp-8(cer22).
However, any missense mutation found in the conserved amino acids of ISY1, PPWD1
and SNRPA1, which are not prompted to present polymorphisms (Figure S4) , would be considered as a candidate for being a modifier of s-adRP caused by PRPF8[R2303G].
C. elegans is a well-established model for drug discovery (39, 40) . Many drugs with an impact on human cells also cause an effect in Drosophila and C. elegans (41, 42) . We assayed a drug library with about 1000 small molecules, most of them FDAapproved, and 16% of them caused an obvious phenotype in C elegans. Our initial objective was to identify a drug capable of rescuing the temperature sensitive sterility of prp-8(cer14) mutants. However, we obtained an unexpected result since drugs produced a stronger phenotype in mutant animals than in wild type. Such result is also clinically relevant since these drugs could have a harmful effect in certain patients. We further validate such negative effect for Dequalinium (DQ), a cytotoxic drug used as antiseptic and disinfectant (43) . DQ and its derivates has been studied for the treatment of distinct cancer types (44, 45) , the use of nanosomes to induce apoptosis by production of ROS (46) , and the mitochondrial targeting in nanomedicine (47) .
Similar to genetic modifiers, the negative effect of some drugs would be gene and/or mutation specific, but our result certainly opens a new venue to study the potential damaging effect of common drugs that may accelerate the progression of the disease in some patients.
MATERIAL AND METHODS
C. elegans strains and maintenance
Worms were cultured and managed following standard methods (48) . Thus, worms were grown on NGM (Nematode Growth Media) agar plates previously seeded with an overgrown culture of the Escherichia coli strain OP50 at temperatures between 15 and 25°C depending on the experiment. Synchronization of worms was done following the sodium hypochlorite treatment (49) .
Bristol N2 was used as the wild type strain. All other strains are listed next: CER255
III; cyn-15 (cer119[D74Q]) I).
Brood size and DAPI staining
For brood size assessment L4 larvae of each strain were singled out in 35-mm NGM agar plates and transferred to a fresh plate daily until egg laying stopped. Two days after P 0 was removed the number of F 1 larvae from each plate was manually scored.
DAPI staining was performed recovering worms in M9 and placing them onto a slide. 
CRISPR editing
prp-8 and snrp-200 mutant worm lines were generated via CRISPR Cas9-triggered homologous recombination following previously described methods (51, 52) . All reagents including crRNAs, Alt-R™ CRISPR-Cas9 tracrRNA, Cas9 Nuclease 3xNLS and primers were obtained from Integrated DNA Technologies (IDT). crRNAs containing a guide sequence with an adjacent protospacer motif (PAM) was injected with purified Cas9 enzyme and dpy-10 crRNA with ssODN dpy-10(cn64) as a co-injection marker for each mutation.
To generate the prp-8(cer22[R2303G]) mutation the crRNA was located in the 9th exon of prp-8 (AGTACTATCATGAAGATCATCGG). Single point mutation was identified by single worm genomic PCR of dpy-10 Rol mutants using specific primers (Fwd-TATGGTGTATCGCCACCTGA; Rev-GAAGTGAACCGGCCGATG for wild-type; Rev-GAAGTGAACCGGGCCGTG for the mutant), alternatively a BceAI restriction site was also located in the mutant strain. The small indel allele cer14, obtained with the same crRNA, is identified using the specific reverse primer TTATGGAAGTGAACCGGCCC.
The snrp-200(cer23[V676]) mutant was created through homology-directed repair using a crRNA guide sequence where the PAM was within the snrp-200 exon 3
(TCCAATATATTGTTGCTCGAGGG). The mutant was identified using specific primers (Fwd-GTGATCGTTTGTACGCCGGA, Rev-TATATTGTTGCTCGAGGGGAAC for wild-type;
Rev-TACTGCTGTTCCAGAGGGAG for the mutant). Allele cer24[S1080] was generated using a crRNA guide sequence located in the 5 th exon of snrp-200 (GTCTTCGTGGCTCAGAGTGCCGG). Identification of the mutant was made by simple PCR using specific primers (Fwd-CTCATCACAAATCACTCGGAG; Rev-GAAGAGTCGTCCGGCACTC for wild-type; Rev-GAAGAGTCGTCCGGCGAGT).
isy-1 (cer115[G170S] ) and cyn-15(cer119[D74Q]) were generated as described above.
crRNA guide sequences used for injection: isy-1 GGTTACTTGGATGACGAAGATGG and cyn-15 ATAATCACTGCAAGCGTCGATGG. The identification of mutant lines was done by PCR with specific primers: isy-1 (common Rev-CCGCTCAGTTTACTTGTATT; Fwd-TTACTTGGATGACGAAGATGG for wild-type; Fwd-GTTACCTTGACGATGAGGACTC for mutant) and cyn-15 (common Rev-CCTCAATTATCTTGACTGGCG; Fwd-TAATCACTGCAAGCGTCGAT for wild-type; Fwd-TAATCACAGCGTCTGTGCAA for mutant).
Developmental delay assay
Worms were synchronized using the sodium hypochlorite treatment (49) . Each strain was seeded in an OP50 plate and let recover for 1 h at 20°C and 25°C. After that, they were singled onto small plates containing OP50 bacteria and grown at the corresponding temperature.
The stage of the worms was determined every 24 h during a 3 days period. Stage determination was based on size and development of body structures like vulva and the size of the gonad.
RNAi screen
128 splicing-related RNAi clones were selected from the literature (21) . Bacteria expressing dsRNA was obtained from ORFeome library (53) or Ahringer library (54) 
Drug validation in agar plates
Validation was done in duplicates in 35-mm plates containing NGM with OP50 that was freeze-thawed three times at -80 
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Figure S2. Developmental delay of s-adRP mutants at 20°C
Developmental progress of singled, mutant and wild-type, L1 larvae was monitored every 24 h for 3 days at 20 • C. Every dot represents a worm (n=25). Dots inside the shaded area indicate presence of embryos in the plate. Dots inside the green area indicate presence of L1, from the F 1 , in the plate. 
Figure S5. Worms presenting an observable phenotype upon drug treatment have a reduced motility
Violin plot and boxplot of the motility of wild-type (N2) and prp-8(cer14) worms, classified by the presence or not of an observable phenotype after drug treatment. prp-8(cer14) presents reduced motility even at control conditions. In both, N2 and prp-8(cer14), the motility is drastically reduced in case of drugs causing harmful effects. Note that N2 is not directly comparable to prp-8(cer14) due to the contribution of F 1 in the control worms to the motility, but not in prp-8(cer14). Box-plot indicates the median with the IQR and whiskers ± 1.5 product of IQR. Motility was measured using the wmicrotacker device. 
